Page 16 - 81_02
P. 16
Problems associated with the emission of pharmaceutical products to the environment
57. Grenier, J-F. Maturity of Global Pharma Market Ternes N. Consumption and Ocurrence. Human
confirmed. PharmaExpand Exchange. Disponible en: Pharmaceuticals, Hormones and Fragances. In: Ternes T.
(pharmaexpand.com/wordpress/?p=223) 2013. y Joss A., Eds. The challenge of micropollutants in urban
water management IWA Pub. Londres 2006.
58. KNAPPE project. Knowledge and Need Assessment
on Pharmaceuticals Products in Environmental Waters. 73. Lienert J, Bürki T, y Escher BL. Reducing
Final report. 2008. micropollutants with source control: substance flow
analysis of 212 pharmaceuticals in faeces and urine. Water
59. Boxall, AB. et al. Pharmaceuticals and Personal Care Sci. Technol. 2007; 56: 87-96.
Products in the Environment: What Are the Big
Questions? Environm, Health Perspectives, 2012; 120, 9: 74. Celiz M D, Tso J. y Aga DS. Pharmaceutical
1221-1229. metabolites in the environment: Analytical challenges and
ecological risks. Environm. Toxicol. Chem. 2009; 28, 12:
60. Alder A, Bruchet A, Carballa M., Clara M, Joss A, 2473-2484.
Löffler D, McArdell C., Miksch K, Oimil F, Tuhkanen T y
Ternes N. Consumption and Ocurrence. Human 75. Walgren, JL Mitchell MD y Thompson DC. Role of
Pharmaceuticals, Hormones and Fragances. In: Ternes T. y metabolism in drug induced idiosyncratic hepatoxicity.
Joss A, Eds. The challenge of micropollutants in urban Cri. Rev. Toxicol.2005; 35: 325-361.
water management IWA Pub. Londres 2006.
76. Nalec-Jawecki, G. Evaluation of the in vitro
61. BIO Intelligence Service. Study on the Environmentl biotransformation of fluexetine with HPLC, mass
risks of medicinal products. Executive Agency for Health spectrometry and ecotoxicological tests. Chemosphere,
and Consumers. Paris 2013. 2007; 70: 29-35.
62. Simó Miñana J. Utilización de medicamentos en 77. European Environmental Agency. (EEA).
España y Europa. Atención Primaria, 2012; 44, 6: 335- Pharmaceuticals in the Environment. Results of an EEA
347. workshop. Copenhagen. 2010.
63. Le Pen C, Lemasson H. y Roulliere-Lelilec C. La 78. Roig B. Ed. Pharmaceuticals in the Environment.
consommation medicamenteuse dans 5 pays eropeén: une Current knowledge and need assessment to reduce
reévaluaation. LEE (Les entreprises du medicament).Paris presence and impact. IWA Pub. Londres 2010.
2007.
79. Boxall AB. Fate of veterinary Medicines Applied to
64. Kümmerer K. Pharmaceuticals in the Environment. Soils. En: Kümmerer K. Ed. Pharmaceuticals in the
Sources, Fate, Effects and Risks. Springer-Verlag. Berlin. Environenment. Sources, fate, Effects and Risks. Springer-
2nd. ed. 2004, 3rd ed. 2008. Verlag. Berlin, 2008.
65. BIO Intelligence Service. Study on the Environmentl 80. Cabello FC. Heavy use of prophylactic antibiotics in
risks of medicinal products. Executive Agency for Health aquaculture: a growing problem for human and animal
and Consumers. Paris 2013. health and for environment. Environ. Microbiol.2006; 8:
1137-1144.
66. Sacher F, Ehmann M, Gabriel S. Graf C. y Brauch HJ.
Pharmaceutical residues in the river Rhine-results of a one- 81. Scottish Environment Protection Agency (SEPA). The
decade monitoring programme. J. Environm. occurrence of chemical residues in sediments in Loch
Monit.2008;,10: 664-670. Erisort, Loch Roag and Loch a Chain Baihn. Sea Loch
Survey, 2012.
67. Bernard M, Arnols M, Edder P y Ortelli D.
Micropollutants in the wáter of the river Rhône-2006 82. Sadezky A, Löffler D, Schlüsener M., Roig B. y
Campaign. Rapp. Comm. Int. prot. Eaux Léman contre Ternes T. Real situation: Occurrence on the main
pollut. Campagne 2006: 163-172. 2007. investiged PPs in water bodies. En: Roig B, Ed.
Pharmaceuticals in the Environment. IWA Pub. Londres,
68. Larsson JD, de Pedro C y Paxeus N. Effluent from 2010.
drug manufactures contains extremely high level of
pharmaceuticals. J. Hazard. Mater. 2007; 148: 751-755. 83. Airis AZ , Shamsuddin AS y Praveena SM.
Occurrence of 17a-ethynylstradiol (EE2) in the
69. Fick J, Söderström H, Lindberg RH, Phan C, Tysklind environment and effect on exposed biota: a review. Env.
M. y Larsson JD. Contamination of surface, ground and Int.2014; 69: 104-119.
drinking water from pharmaceutical production.
Environm. Toxicol. Chem.2009; 28: 2522-2527. 84. Zabczynski S, Buntner D, Miksc K. y Roig B.
Performance of conventional treatment processes of the
70. Daughton CG y Ruhoy IS. Environmental Footprint of most resistant PPs. En: Roig B, Ed. Pharmaceuticals in the
Pharmaceuticals- The Significance of Factors Beyond Environment . AGA Pub. Londres, 2010.
Direct Excrection to Sewers. Environm. Toxicol.
Chem.2009; 28, 12: 2495-2521. 85. Sadezky A, Löffler D, Schlüsener M, Roig B. y Ternes
T. Real situation: Occurrence on the main investiged PPs
71. BIO Intelligence Service. Study on the Environmentl in water bodies. En: Roig B. Ed. Pharmaceuticals in the
risks of medicinal products. Executive Agency for Health Environment. IWA Pub. Londres, 2010.
and Consumers. Paris 2013.
86. Sadezky, A., Löffler,D., Schlüsener,M., Roig, B. y
72. Alder A, Bruchet A, Carballa M, Clara M, Joss A., Ternes, T. Real situation: Occurrence on the main
Löffler D, McArdell C, Miksch K, Oimil F, Tuhkanen T y
@Real Academia Nacional de Farmacia. Spain 99
